More people are now advised to get a pneumococcal vaccine if they haven’t already, as CDC advisors recommended the shots for ...

Americans as young as 18 with a chronic condition can now receive an RSV vaccine after Pfizer snagged expanded FDA approval ...

The UK medicines authority approved Eli Lilly’s Alzheimer’s drug Kisunla on Wednesday, making it the third major market to ...

Thermo Fisher told investors it is ready to shut the door on 2024, anticipating biotech funding to improve and lingering ...

Antitrust regulators shouldn't clear Novo Holdings' planned acquisition of Catalent, Roche CEO Thomas Schinecker said ...

A venture capital firm that seeks to digitize the life sciences ecosystem has plans for a $500 million follow-up fund, ...

Alto Neuroscience’s stock tumbled 60% on Wednesday morning, the day after the company said a mid-stage trial for its oral ...

A nimble Houston startup has raised a concise $28.4 million Series A to start a mid-stage trial. The company, named March ...

Roche’s competition in the eye disease space is intensifying with Renegeron’s high-dose Eylea and looming biosimilar ...

Eccogene's $60M milestone from AstraZeneca: The payment arrived after Eccogene met several milestones, including dosing the first ...

Be Bio's $82 million round announced Tuesday will help the Cambridge, MA-based biotech fund work for two of its drugs in ...

UCB will advance its anti-tau antibody for Alzheimer’s disease solo after Roche and Genentech walked away from the asset ...